Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.99% 25.00p 24.00p 26.00p 26.75p 25.00p - 23,964 16:55:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.2 -6.7 -4.1 - 52.08

Amryt Pharma (AMYT) Latest News

More Amryt Pharma News
Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
21/6/201721:55Amryt Pharma1,242
27/3/201708:19Amryt Pharma108
21/4/201610:07AMYT1
21/4/201610:04Amryt Pharma2

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:39:3325.1019,8964,993.90O
09:11:2925.309123.02O
07:30:5525.302,000506.00O
07:30:1825.001,727431.75O
07:01:4225.0025062.50O
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

DateSubject
22/6/2017
09:20
Amryt Pharma Daily Update: Amryt Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 25.25p.
Amryt Pharma has a 4 week average price of 23p and a 12 week average price of 20p.
The 1 year high share price is 28.75p while the 1 year low share price is currently 13.75p.
There are currently 208,339,631 shares in issue and the average daily traded volume is 158,001 shares. The market capitalisation of Amryt Pharma is £52,084,907.75.
13/6/2017
16:52
icebreaker: If the share price is up 6% on minuscule volume, I would think there is something interesting in the pipeline - possibly an RNS in the morning and more clarity in tomorrow evenings presentation. After all, they are surely not trotting the same information out that the market is already aware of!
25/4/2017
11:44
bigwavedave: Can't post the link so c&p here: Company news Amryt Pharma (LON:AMYT, 23.38p) – Speculative Buy Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, yesterday announced that it has enrolled first patient for its Phase III clinical trial (EASE study) of AP101 for Epidermolysis Bullosa ('EB'). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin with currently no approved therapy. Amryt expects to conduct these trials in approximately 15 countries at over 30 sites to enrol a total of 164 evaluable patients. Patients will be randomised in a double-blind fashion to AP101 or placebo, and the proportion of patients with completely healed target wounds within 45 days will be evaluated as the primary efficacy endpoint. An interim analysis will be conducted when 50% of the study patients have completed 45 days of treatment. The results from this interim analysis of this trial are expected in the Q1 2018. Amryt's Chief Medical Officer, Mark Sumeray, commented "The trial will evaluate the efficacy and safety of our lead drug candidate, AP101, as a potential treatment for Epidermolysis Bullosa, a distressing and rare skin disorder. We look forward to further patients joining the study, which we expect to be one of the largest studies of its kind in this rare disease". Our view: Amryt has now passed an important milestone, the first patient first visit, for its lead drug candidate, AP101. AP101 (Episalvan), is a prospective treatment for EB, a rare and distressing genetic skin disorder which has achieved Orphan Drug Designation in both the US and EU. There is currently no treatment available for EB, which affects approximately 500,000 people worldwide, with global market for a treatment estimated to be in excess of €1.3bn. Very importantly, the Group has funding and facility sufficient to carry AP101's development through to expected release of its key Topline Data during Q3 FY2018, while also supporting more modest on-going spend for AP102 (Pre-clinical stage for Acromegaly and Cushing's Disease). On top of this, the Group is already generating revenues from the excellent Lojuxta licensing deal struck back in December 2016. This has created a diversified pipeline of therapies ranging from earlier to later stage development along with a commercial offering which together target multiple Rare (or Orphan) Diseases. Such products do not just benefit from extended market exclusivity and reduced R&D costs right across the globe, but also enjoy a major pricing advantages which average five-times that of traditional prescriptive products. While its business plan is just about unique in Europe, there is large NASDAQ-listed sub-sector of comparables which command a significant valuation premium to Amryt, despite most being pre-revenue and somewhat earlier in their development. The fact that a discounted-NPV for Lojuxta, its low-risk, high margin licensed treatment for HoFH (Homozygous Familial Hypercholesterolemia) alone, significantly exceeds the Group's market capitalisation, still need to be recognised in the share price. Such anomalies, of course, can and do correct. For Amryt this cannot be long away. Significant upside potential. Beaufort reiterates its Speculative Buy rating on Amryt Pharma. Beaufort Securities provides Investor Relations services to Amryt Pharma plc
07/4/2017
11:43
curnic1: Stifel broker note: Report card – an impressive first year Amryt Pharma is a specialty pharma company focused on acquiring, developing and commercialising drugs for the treatment of rare and orphan diseases. The company has had a frenetic first year as a public company. Having acquired two orphan drug development assets (Episalvan and AP102) in April 2016, the company went on to obtain European rights to Lojuxta to treat HoFH, a rare and fatal genetic disease, as well as securing a preferential €20 million EIB loan to fund future developments. With an encouraging start to Lojuxta sales, we recently added the product to our valuation of Amryt. Our 60p target price reflects the substantial upside opportunity we believe Amryt offers investors. Reiterate Buy. Phase III trial of Episalvan in epidermolysis bullosa (EB) pending. In March 2017, Amryt reached agreement with the FDA and EMA to a single pivotal trial design for a Phase III trial of Episalvan in EB. The blinded trial is expected to recruit 164 evaluable patients who will be treated for 90 days. The primary endpoint of the trial will be the proportion of patients with completely healed target wounds within 45 days. Secondary endpoints include time to wound healing and changes in pain and itch. An interim efficacy analysis, likely to occur in 1Q18, will be conducted after half the patients are recruited. Results from the trial are expected in 2H18. Thirty clinical sites in 15 countries have already been pre-qualified to participate in the study. We forecast sales of Episalvan in EB of $258 million by 2023 with launch in 2019. With around 55,000 sufferers in the US and Europe, EB represents a significant orphan drug condition with no current treatment other than regular bandaging. The genetic disorder is life threatening and represents an area of high unmet medical need. Lojuxta brings Amryt a commercial asset with growing sales. In December 2016, Amryt secured European commercial rights from Novelion Therapeutics Inc. to Lojuxta, an approved drug for the treatment of homozygous familial hypercholesterolaemia (HoFH), a rare and fatal genetic disease that results in extreme elevated cholesterol levels in the blood and formation of cholesterol deposits. In March 2017, Amryt announced Lojuxta sales achieved an annual run-rate of €10.5 million in its first three months. The company expects the product to be immediately self-funding. Reiterate Buy. We recently raised our target price reflecting our first time inclusion of Lojuxta in our valuation. Our target price is based on a hybrid of NPV, comparative and discounted revenue multiple methodologies. Our target price at 60p per share implies significant upside potential to the current share price.
29/3/2017
17:42
icebreaker: I am assuming that tomorrow's figures up to 31 December 2016 are unlikely to show any meaningful revenue and to that extent, as long as there are no negative shocks the price is unlikely to fall. The loss should be well and truly factored in to the current share price! Is this a view shared by others?
01/3/2017
11:37
gnnmartin: papillon, I've long ben intrigued by strange reported trades: trades of 1 share being the obvious example. Having read Flash Boys, I wonder if it is automatic trading software, though I don't really expect bots to be interested in small cap shares: at least, the bots that Flash Boys talks about were (IIUC) only interested in shares that trade in five figure dollar amounts. The starting point for designing a bot program is much like chart based trading: look at the recent trades and decide which way the share price is going to move, but whereas the chartist is interested in movement over the next days to months the bot is interested in movement over the next seconds to minutes. In the case of Flash Boys, the bot is interested in the movement over the next few microseconds. However, pseudo charting is just the starting point. Much like the game of 'paper, scissors, stone', or indeed like poker, the bot hopes to work out what other traders intend to do by studying what they have recently done. Naturally, bots will then take steps to ensure that other bots (and human traders) don't twig what the bot intends, or even are positively misled as to the bots intentions. Humans can do the same: as did that guy from London who made millions trading on Nasdaq and has just lost his fight to avoid extradition to the USA where he faces charges of distorting the market. The moral is that it is dangerous to make too much money on the USA market even if you are only using the same trading techniques as the big boys are using in the USA. In the USA (metaphorically speaking) poker games often end in gun fights. So, why the single share trades? Obviously this has to be done by a bot (or person) that pays millipence per trade, which rules out me! But I guess that there are some bots that look at the number of trades in the last hour (say), or look at the average price of the last 5 deals (again, I'm trying to imagine something fairly believable, nothing more accurate than that). In this case the bot that is placing the single share trades reckons that some other bot or bots might be interested in that security and wants to 'paint a picture' (as Tom Wolfe put it, in Bonfire of the Vanities). The pictures are not necessarily only aimed at other bots. People tend to look at closing prices and the movement reported during the day, or at some automatic report of closing/opening/current price, and the various media use different ways of reporting. You have probably noticed that ADVFN, LSE, III, and other can sometimes report quite different data for closing prices, current movement, and so forth. A bot that posts 5 trades of one share might be aimed at influencing one or more of these data channels. It's a bit like the ways that city boys nudged the LIBOR (etc.) rates by reporting phoney interest in loans. As ever, the line between clever negotiating and dishonest trading is blurred, and the clever negotiator who is too successful is liable to find him (or her) self described as dishonest. One oddity that blossomed recently is the reported trade that is deleted and then immediately re-instated. For example, a trade of £10,000 at 10p per share might be deleted and immediately re-instated some hours or even a day later, by which time 10p lies well outside the current quoted spread. The honest reason for deleting and reinstating a trade is that you failed to mention that there were bargain conditions attached (say), or you got the bargain price wrong, or the quantity, or such like, but in almost all, perhaps all, examples I have noticed, the trade deleted is then reposted without any change. I notice that some media channels report the number of shares traded and fail to count a deleted trade as positive. If (for example) 100,000 shares are reported as traded at 10p at 8:00, and then at 12:00 it is reported that at 8:00 100,000 shares were wrongly marked as traded at 10p, and then at 12:01 it is reported that at 8:00 100,000 shares were traded at 10p, then some data streams add 300,000 shares to their tally of trades during the day, giving a false impression of trading activity. I expect too that some people (or bots) will get a false impression of the current share price when a big trade is posted at what is in effect an old price. I could go on, but I guess that is more than enough for something fairly off thread. All guesswork.
04/12/2016
09:36
buffythebuffoon: No JP, stop anchoring on a share price! This is a biopharma that will multibag with any degree of success. The daily movements in the share price are meaningless for investors who bought in having read and understood the business case. Those who passively sat there when AMRYT reversed into Fastnet, without actively looking at the business, need to recognise that they must look to themselves as the problem, not others. After all, instead of doing the square root of zero, they could have sold. Buffy
04/11/2016
16:22
papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p?
19/8/2016
19:29
papillon: dingo75 16 Aug'16 - 13:26 - 295 of 302 1 0 papp lol egg on your FACE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. I'm always ending up with egg on my face, dingo75. However I still believe we will see a small, short term, fall back in the AMYT share price and then the formation of a bullish Inverse Head & Shoulders. You could be right and I will be proved wrong and end up with egg on my face, but I'm hopeful I will soon be proved right. After all a bullish chart formation, after a period of a falling share price, is often the sign that a significant price reversal and subsequent major share price rise is on the cards. Don't throw any more raw eggs at me just yet, dingo75, but keep them ready! LOL.
27/7/2016
17:41
jacksonpollack: Point is it wasn't a dog and sound share price is flying up over 150% in past 3 weeks. Once the full extent of the gas find comes out the sky is the limit regarding their share price fastnet knew what was there and had the data to back it up. They just took the decision not to carry on with it. Shame as look where we are today, over 40% down on rip off consolidation share price and miles away from share price when we had Tendrara.
01/5/2016
21:27
papillon: Amryt Pharmaceuticals is worth a closer look By Gary Newman | Sunday 1 May 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. As usual I had a great day at the UK Investor Show, especially listening to many of the informative speakers on the main stage. When it came to the companies exhibiting, to be honest there are many of them which I wouldn’t dream of putting my money into – either because I view them as poorly run or vastly over-valued at their current share prices. But there were also some that look to have good potential for the future, as well as offering value, and are definitely on my watch list, and amongst them was recently listed Amryt Pharmaceuticals (AMYT) which completed a reverse takeover into Fastnet Equity and was admitted to trading a couple of weeks ago. I previously covered this company as a buy at 2.9p one weekend back in late February, but it was then suspended before open on the Monday morning when news of the deal was confirmed, and you can now get in even cheaper as the opening day price of 24p (equivalent to 3p prior to the deal) has subsequently dropped to under 20p to buy. It is still early days and like any similar stage pharmaceutical company it does carry a fair amount of risk, but unlike many of the AIM listed ones it does at least have a product, Episalvan, that is already approved in the EU, Norway and Iceland, and also has further potential for development to treat other diseases. Amryt has a very short history as it was only formed in August of last year, but that came about via the acquisitions of German bio-tech Birken AG and Swiss pharmaceuticals company Sompharmaceuticals SA. It also has a team behind it that have a good track record in the industry, with chairman Harry Stratford having previously built two successful listed pharma companies (including Shire which is now FTSE100 listed), and CEO Joe Wiley and CFO/COO Rory Nealon who have years of experience in life sciences. Its licenced product Episalvan is used to treat partial-thickness wounds in adults, but the company is looking to extend that to epidermolysis bullosa, which commonly occurs in children, and is expecting to begin phase three trials in the second half of this year. The company currently has orphan status in both the US and EU for this potential EB treatment, meaning that not only will it get tax breaks but also an exclusivity period to develop a cure for this condition. The only downside with that is that orphan drugs tend to be less profitable than those that cure common illnesses, but can still be very lucrative and the global EB market is estimated at $1.5 billion per annum, so the company won’t even need a big slice of that to succeed. Amryt also has the Imlan brand (developed by Birken) which is on sale and is used by people suffering from dry skin and other dermatitis conditions. There are also a couple of other drugs, but they are yet to undergo clinical trials and are too early a stage to really be that relevant at the moment, although that could well change in the future. In terms of the financials it is very hard to get a real grip on these as there isn’t a lot to go on by way of figures, other than that the company raised a gross amount of £10 million at 24p when it listed in April, and prior to that it also had close to £10 million in the bank. The total amount paid for the takeover of Amryt was just under £30 million in shares and was settled by the issue of 123 million shares (circa 59%) in the new company, with those who originally sold Birken receiving 30 million of those, and 12 million going to former Som owners. Since relisting it should have paid Birken €10 million as a milestone payment for the Episalvan EU approval, with potentially a further €40 million to pay in the future, plus royalties on this product of 6-9% of sales for a ten year period. For a company of this size there is a relatively small freefloat, with over 62% of shares not in public hands, and the Software AG-Stiftung fund owning 20.9%, and previously having funded Birken to the tune of around €54 million to develop its products. There is too much to go into every detail, so I would suggest that anyone interested in investing reads the admission document before doing so, and also realises that this does still have risks attached if it is going to justify its current market cap of £42 million. But I think the current share price, or possibly even slightly lower if you get he chance, offers a good buying opportunity as I think many people piled into this one expecting fireworks overnight. But typically of many PIs, when that didn’t happen they have gradually got bored and sold to chase riches elsewhere, and that has dragged the share price down to where it is. That unfortunately is also one of the disadvantages of a small freefloat as it doesn’t take a lot of selling to have a disproportionate affect on the share price, but that also works the other way at times when the shares are in high demand, such as after good news. So for me overall this is a speculative buy at these levels, especially given how far along the road it is with its products compared to many similar sized pharmas. Just be aware that it will need to raise further funding in the future, although that might not need to be via equity issue given previous funding from the biggest shareholder. - See more at: HTTP://www.shareprophets.com/views/20422/amryt-pharmaceuticals-is-worth-a-closer-look#sthash.2A4X4B41.dpuf
Amryt Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170622 16:43:49